title: Esophagitis in Adolescents.
abstract: Esophagitis is the end result of a variety of insults to epithelial homeostasis. Eosinophilic esophagitis is a manifestation of non-IgE-mediated food allergy that most commonly affects the esophagus of males who have other atopic phenomena. Reflux esophagitis reflects repeated exposure to acidic gastric contents because of failure of the normal protections afforded by the LES. Because certain histologic features can be present in either condition, endoscopic biopsy alone does not distinguish them. Their symptoms overlap, but the treatment options are very different, such that making a formal diagnosis by following consensus guidelines is essential. A treatment protocol designed to manage the inflammation by controlling the provocative factors (acid for GERD and food antigens for EoE) or suppressing the inflammation (ie, topical steroids for EoE) should result in normalization of the mucosa and resolution of symptoms. Eosinophilic esophagitis is a chronic condition that rarely remits spontaneously, so any therapeutic modality will need to be continued indefinitely.
authors.forename: Philip E
authors.initials: PE
authors.lastname: Putnam
mesh_terms: D000293:Adolescent; D019819:Budesonide / Q000627:therapeutic use; D004035:Diet Therapy; D057765:Eosinophilic Esophagitis / Q000175:diagnosis / Q000628:therapy*; D050782:Esophageal pH Monitoring; D004942:Esophagitis, Peptic / Q000175:diagnosis / Q000209:etiology / Q000628:therapy*; D000068298:Fluticasone / Q000627:therapeutic use; D018662:Fundoplication; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D005938:Glucocorticoids / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*
chemical_list: D005938:Glucocorticoids; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D019819:Budesonide; D000068298:Fluticasone